Glutathione Side Effects: What the Research Documents

Short answer: what happens depends almost entirely on the route. Oral and topical glutathione have been studied in small randomised trials and reported good short-term tolerability, with mild effects only.⁴ Intravenous (IV) glutathione pushed for skin lightening is a different story: regulators and dermatology reviews document severe cutaneous reactions including potentially fatal Stevens–Johnson syndrome and toxic epidermal necrolysis, plus thyroid, kidney and liver dysfunction, severe abdominal pain, and deaths from air embolism or sepsis caused by non-sterile injection.¹² A 2025 systematic review concluded that IV glutathione is contraindicated for this use, for lack of efficacy as much as for its side effects.⁴

The honest caveat that runs through everything below: nobody knows how often any of this happens. Serious events are captured through case reports and passive regulatory reporting, not controlled trials, so no reliable rate exists. And “fewer reports” is not the same as “safe” — a confirmed case of toxic epidermal necrolysis was triggered by oral whitening pills, not injections.³ This page summarises what the peer-reviewed literature and agency advisories actually document. It is provided for research and educational purposes only, is not medical advice, and does not describe a human-use protocol. Consult a qualified healthcare professional before making any health decision.

Documented side effects

Reported effects vary by route (oral, topical, intravenous) and by dose. Most serious signals cluster around unregulated IV administration for cosmetic skin lightening, but severe reactions have also been reported after oral “whitening” pills. The table below lists effects documented in agency advisories, case reports and reviews. Frequencies are not shown because they are not reliably known (see “What we do NOT know”).

The IV skin-lightening risk (regulatory warnings)

The most prominent safety signals come from IV glutathione used cosmetically. The Philippine Food and Drug Administration (FDA-PH) issued a public advisory stating it has not approved any injectable glutathione product for skin lightening; the only injectable indication it recognized was as an adjunct treatment in cisplatin chemotherapy. The advisory warns that off-label IV use for whitening has no supporting clinical-trial evidence and no established dosing, and it lists toxic effects on the liver, kidneys and nervous system, Stevens–Johnson syndrome, a theoretical long-term skin-cancer concern, and the risk of transmitting infections such as HIV and hepatitis B and C when administered in non-sterile or non-medical settings ¹.

Dermatology reviews echo and extend this. IV preparations have a narrow margin between the marketed “effective” dose and doses producing toxicity, and reported harms range from mild transient headache to fatal SJS/TEN, kidney and liver dysfunction, thyroid dysfunction, severe abdominal pain, and fatal complications such as air embolism or sepsis from incorrect IV technique ². A 2025 systematic review of the whole skin-lightening literature went further and concluded that IV glutathione is contraindicated, on grounds of both lack of efficacy and side effects, while judging topical and oral forms moderately effective with minimal and substantial adverse effects respectively ⁴. Critically, oral is not automatically safe: a confirmed case of toxic epidermal necrolysis was triggered by oral glutathione whitening pills ³.

Feeling sick after glutathione: what is actually documented

The most common real-world complaint is not a rare skin catastrophe — it is simply feeling unwell after a dose. Here the literature is thinner than the marketing on either side would suggest, so it is worth being precise about what is and is not recorded.

• After an IV infusion, dermatology reviews describe infusion reactions: nausea, vomiting, chills, fever, tremor, light-headedness and generalised body aches, alongside transient headache.²⁶ These are the symptoms most people mean when they say an infusion made them feel sick.
• After oral glutathione, the randomised trials that exist — at 250 mg once daily, 250 mg twice daily and 500 mg once daily over several weeks — reported good short-term tolerability, with adverse effects described as minimal.⁴ That is reassuring at those doses and durations, and says nothing about higher doses or longer use.
• Mild skin eruptions and rash are reported by both routes.²⁶
• No frequency is established for any of these. No trial was designed or powered to measure how often they occur in cosmetic use, so any percentage circulating online is an invention.

The distinction that matters clinically is between feeling unwell and the start of a severe cutaneous reaction. A rash accompanied by fever, painful or burning skin, blistering, peeling, or sores in the mouth, eyes or genitals is not an ordinary side effect — that is the presentation of Stevens–Johnson syndrome and toxic epidermal necrolysis, which are medical emergencies.¹³ Anyone who develops those signs after taking or receiving glutathione by any route needs urgent medical assessment, not reassurance from a supplement page.

How the risk differs by route

Route is the single strongest predictor of how much risk is on the table, and it is the variable most often left out of the discussion.

Two conclusions follow, and neither is a marketing message. First, the injectable route carries by far the heaviest documented harm and by far the weakest efficacy evidence — the 2025 systematic review calls it contraindicated on both counts.⁴ Second, a large share of the worst outcomes are not properties of the molecule at all: air embolism, sepsis and transmission of HIV or hepatitis B and C come from how and where the infusion is given, in spas and home services outside any clinical governance.¹

Who is at higher risk / contraindications

Because controlled cosmetic-use safety data are lacking, risk is inferred from the documented signals and general pharmacovigilance. Groups where caution is repeatedly flagged include:

• Anyone with a history of severe drug eruptions (SJS/TEN), drug allergies, or asthma/atopy — hypersensitivity and severe cutaneous reactions are documented ¹²³.
• People with pre-existing kidney, liver, or thyroid disease, given the reported organ effects ¹².
• Anyone receiving unregulated IV infusions in non-clinical settings (spas, home services), where air embolism, sepsis and blood-borne infection risks concentrate ¹².
• Pregnancy and breastfeeding: safety is not established.
• People on other medications, where interactions are uncharacterized.

This is not an exhaustive contraindication list; individual risk can only be assessed by a licensed clinician.

What we do NOT know

The evidence base has real gaps, and it is important not to mistake absence of data for proof of safety:

• Incidence is unquantified. Serious events are captured mainly through case reports and passive regulatory reporting, not controlled trials, so a reliable rate (how often SJS/TEN, thyroid or renal effects occur) cannot be stated.
• No long-term safety data. The consequences of repeated or high-dose systemic glutathione for cosmetic use over months to years have not been studied in large trials ¹⁶.
• IV dose–toxicity threshold is undefined. There is no established safe dosing regimen for skin-lightening IV use ¹⁴.
• Oral/topical tolerability is short-term only. The few randomized trials that reported good short-term tolerability were small and brief ⁴⁶; they do not establish long-term safety, and severe oral reactions have still occurred ³.

Where reports are simply lacking for a given outcome, that reflects limited study — not demonstrated safety.

Dosage & handling reference

For laboratory and research documentation of reconstitution and handling figures, see the Glutathione dosage reference and the peptide dosage calculator. For background on the molecule itself see what glutathione is and what it does, and for what the trials measured on skin tone, glutathione before and after. These tools exist for research recordkeeping and calculation only. They are not human-use instructions, do not endorse cosmetic or self-administered use, and do not override the risks described above. Any decision involving glutathione in a person should be made with a qualified healthcare professional.

FAQ

Is glutathione safe because it is a natural antioxidant the body makes?

Being endogenous does not make supplemental or injected glutathione risk-free. The documented harms above — SJS/TEN, thyroid, kidney and liver effects — are tied to how it is administered, especially unregulated high-dose IV, not to whether the molecule occurs naturally.¹²

Is oral glutathione safer than IV?

The documented harm is far lighter by mouth, and the randomised oral trials at 250–500 mg/day reported good short-term tolerability.⁴ But this page does not present any route as “safe”. A confirmed toxic-epidermal-necrolysis case was caused by oral whitening pills, so severe cutaneous reactions are possible by mouth too.³ Those trials were brief and do not establish long-term safety. Fewer reports is not the same as proven safety.

Why do I feel sick after a glutathione infusion?

Nausea, vomiting, chills, fever, tremor, light-headedness, body aches and headache are described in dermatology reviews as infusion reactions to IV glutathione.²⁶ How often they occur has never been measured in a controlled study. Symptoms that come with fever plus a painful, blistering or peeling rash, or sores in the mouth or eyes, are a different matter and need emergency assessment.¹³

Do regulators approve IV glutathione for skin whitening?

No. The Philippine FDA states that no injectable glutathione product is approved for skin lightening and warns against the practice; injectable glutathione was recognised only as an adjunct in cisplatin chemotherapy.¹

How long do the side effects last?

Infusion reactions and transient headache are described as self-limited.²⁶ Organ effects on the thyroid, kidneys and liver, and severe cutaneous reactions, are not self-limited and are the reason the advisories exist.¹ No study has followed cosmetic users long enough to describe a recovery timeline, so any specific duration quoted elsewhere is not evidence-based.

References

1. Food and Drug Administration, Republic of the Philippines. FDA Advisory No. 2019-182: Unsafe use of glutathione as skin lightening agent. fda.gov.ph
2. Sonthalia S, Jha AK, Lallas A, Jain G, Jakhar D. Glutathione for skin lightening: a regnant myth or evidence-based verity? Dermatol Pract Concept. 2018;8(1):15–21. PMID: 29445569. doi:10.5826/dpc.0801a04
3. Chottawornsak N, Tansrisawad N, Tubtimrattana A, et al. Glutathione whitening pills induced toxic epidermal necrolysis: an unusual case confirmed by ELISpot and LC-MS. Dermatitis. 2021;32(6):e115–e117. PMID: 34608063. doi:10.1097/DER.0000000000000782
4. Sarkar R, Yadav V, Yadav T, Janaani P, Mandal I. Glutathione as a skin-lightening agent and in melasma: a systematic review. Int J Dermatol. 2025;64(6):992–1004. PMID: 39444151. doi:10.1111/ijd.17535
5. Davids LM, van Wyk JC, Khumalo NP. Intravenous glutathione for skin lightening: inadequate safety data. S Afr Med J. 2016;106(8):782–786. PMID: 27499402. doi:10.7196/SAMJ.2016.v106i8.10878
6. Sonthalia S, Daulatabad D, Sarkar R. Glutathione as a skin whitening agent: facts, myths, evidence and controversies. Indian J Dermatol Venereol Leprol. 2016;82(3):262–272. PMID: 27088927. doi:10.4103/0378-6323.179088

Research use only. This content is for informational and research documentation purposes and is not medical advice, diagnosis, or treatment. It does not encourage human use of glutathione. Consult a licensed healthcare professional before making any decision.